Andros Medicines Inc.
New Form D on file · 2026-07-01 · the record
What the record says
Trailing twelve months. 148 filings in Pharmaceuticals, totalled by week. The dot is this raise, $3.05M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
John Maraganore is named as Executive Officer and Director on the Form D that Andros Medicines Inc. filed with the SEC on 1 July 2026, one of 3 people that filing names.
Khalil Barrage is named as Director on the Form D that Andros Medicines Inc. filed with the SEC on 1 July 2026, one of 3 people that filing names.
Antoine Barouky is named as Director on the Form D that Andros Medicines Inc. filed with the SEC on 1 July 2026, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2026-07-01 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 3 people named on the filing — 1 holding an executive role and 2 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Andros Medicines Inc.
- Source Check — verify John Maraganore's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with John Maraganore for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Andros Medicines Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Andros Medicines Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.